Emerging life sciences company, NuSep Limited (NSP) announced that it will enter the US$1 billion Asian blood plasma market through a 38% (S$4m) investment in Singapore-based blood fractionation business, SingaPharm Pte Ltd. SingaPharm has developed a totally disposable “mini-mill” plasma fractionation process based on NuSep’s patented PrIME separation technology. NuSep is also pleased to announce that a leading Singapore cornerstone investor will invest S$3 million in SingaPharm. The total investment required to set up the manufacturing facility and fund clinical trials of SingaPharm’s mini-mill concept is S$12m.
Singapore’s Health Sciences Authority (HSA) has reviewed SingaPharm’s technology and clinical trials will commence shortly. Once regulatory approval is gained from Singapore’s HSA, NuSep expects that the mini mill concept will be adopted by a number of smaller Asian nations that wish to become self sufficient in blood plasma manufacturing. The mini mill concept incorporates NuSep’s proprietary PrIME technology which provides disposable modular manufacturing for plasma proteins. NuSep will secure additional recurring revenue streams from the ongoing supply of its unique disposable membranes which are solely manufactured in Lane Cove, Sydney. NuSep will sell SingaPharm for S$9.5m a license to manufacture and sell plasma products including: Albumin and IVIG. This S$9.5m payment will be converted into equity on the sale of the first plasma product resulting in NuSep owning 51% interest in SingaPharm.
NuSep Managing Director, Dr. Hari Nair, said: “This investment in SingaPharm is a significant development for NuSep as it builds on our base technology and cements NuSep as a technology provider. Not only does it provide the company with a new growth platform in the $1 billion Asian blood plasma market but it also helps to open a new profitable business line for the company”
NuSep (NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from Fraction to Function. The company has offices in both Sydney Australia and Atlanta, USA. With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world’s first IVF sperm separation device.
In short NuSep has redefined the BioSeparations market through innovation and simplification. SingaPharm is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. SingaPharm is currently a wholly owned subsidiary of NuSep Holdings Limited (NSP). SingaPharm’s process is based on the Preparative Isolation by Membrane Electrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.
http://www.traderdealer.com.au/Fundamentals/nsp
Tags: acquisition, Healthcare, NSP, Nusep
